Forskning
Udskriv Udskriv
Switch language
Hvidovre Hospital - en del af Københavns Universitetshospital
Udgivet

Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  1. CT and MR neuroimaging findings in patients with Lyme neuroborreliosis: A national prospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Global brain atrophy and metabolic dysfunction in LGI1 encephalitis: A prospective multimodal MRI study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Motor activation in SPG4-linked hereditary spastic paraplegia

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  4. The relationship between MRI and PET changes and cognitive disturbances in MS.

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  • R Iodice
  • A Carotenuto
  • R Dubbioso
  • I Cerillo
  • L Santoro
  • F Manganelli
Vis graf over relationer

BACKGROUND: Clinical trials have shown the therapeutic effect of fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RR-MS), but its influence on nervous conduction assessed by evoked potentials (EPs) has not been previously investigated.

METHODS: EP data of 20 patients examined 12months prior to initiation of fingolimod (t=-1), at treatment initiation (t=0) and 1year later (t=+1) were compared. Each EP (VEP, MEP, SEP) and EP sum score, a global evoked potential score as the sum score of the each EP score was evaluated and correlated with Expanded Disability Status Scale (EDSS).

RESULTS: During pre-treatment period (1year) EDSS worsened while one year after fingolimod treatment EDSS remained stable. From t-1 to t0 VEP, SEP, MEP and EP sum score worsened while from t0 to t+1 VEP, SEP and EP sum score improved, and MEP score remain stable. VEP and SEP were related to EDSS at baseline (t=-1), while MEP and total EP sum score were related to EDSS at all time points.

CONCLUSION: Fingolimod is able to improve visual and somatosensory evoked potential in RR-MS patients even if clinical disability scale remains stable. VEP and SEP could give eloquent information on pathway underweighted in EDSS. EPs are useful to evaluate fingolimod effects in clinical practice.

OriginalsprogEngelsk
TidsskriftJournal of the Neurological Sciences
Vol/bind365
Sider (fra-til)143-6
Antal sider4
ISSN0022-510X
DOI
StatusUdgivet - 15 jun. 2016

ID: 48420053